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ABSTRACT
The B-cell receptor (BCR) plays an important role in the pathogenesis and 
progression of chronic lymphocytic leukemia (CLL). By global microRNA profiling 
of CLL cells stimulated or not stimulated by anti-IgM, significant up-regulation of 
microRNAs from the miR-132~212 cluster was observed both in IGHV gene unmutated 
(UM) and mutated (M) CLL cells. Parallel gene expression profiling identified SIRT1, a 
deacetylase targeting several proteins including TP53, among the top-ranked miR-132 
target genes down-regulated upon anti-IgM exposure. The direct regulation of SIRT1 
expression by miR-132 was demonstrated using luciferase assays. The reduction 
of SIRT1 mRNA and protein (P = 0.001) upon anti-IgM stimulation was associated 
with an increase in TP53 acetylation (P = 0.007), and the parallel up-regulation of 
the TP53 target gene CDKN1A. Consistently, miR-132 transfections of CLL-like cells 
resulted in down-regulation of SIRT1 and an induction of a TP53-dependent apoptosis. 
Finally, in a series of 134 CLL samples, miR-132, when expressed above the median 
value, associated with prolonged time-to-first-treatment in patients with M CLL  
(HR = 0.41; P = 0.02). Collectively, the miR-132/SIRT1/TP53 axis was identified as 
a novel pathway triggered by BCR engagement that further increases the complexity 
of the interactions between tumor microenvironments and CLL cells.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is a neoplastic 
disease characterized by highly variable clinical courses, 
ranging from rapid progression with fatal outcome to a 
relatively indolent behaviour with normal life expectancy 
[1]. In this regard, a more aggressive clinical course 
has been associated with specific features of the B-cell 
receptor (BCR) expressed by CLL cells, particularly 
the so-called unmutated (UM) configuration, i.e. less 
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than 2% point mutations, of the genes coding for the 
immunoglobulin heavy-chain variable (IGHV) region of 
the BCR [1].
The role of the BCR in the pathogenesis and 
progression of CLL is also suggested by the following 
observations: i) about 20% of CLL use biased groups of 
IGHV genes expressing similar/identical HCDR3s and 
identical light chains (stereotyped BCRs), indicating that 
the initial clonal expansions can be antigen-driven [2–5]; 
ii) a strong correlation is observed between the clinical 
course of CLL and expression of certain stereotyped BCRs 
[2, 4, 5]; iii) freshly isolated CLL cells show increased 
expression of BCR target genes and reduced expression 
of surface IgM, suggesting continuous antigen stimulation 
in vivo [6–8]. Moreover, the promising results of clinical 
trials with agents targeting the BCR signaling pathway, 
such as inhibitors of SYK, BTK, and PI3Kδ, again indicate 
that chronic BCR signaling is required for CLL cell 
growth and survival [9–12]. It is worth noting, however, 
that CLL BCRs also display features of auto-reactivity, 
their engagement potentially triggering signaling cascades 
leading to anergy and/or apoptosis, resulting in cell death 
rather than increased survival [13–20]. What outcome 
will predominate is determinate by several factors, 
such as BCR signal intensity, BCR signal duration, and 
availability of co-stimulatory signals [21–23].
MicroRNAs represent a class of small non-
coding RNAs that act as master regulators of protein 
expression by inhibiting the translation or inducing 
the degradation of target mRNAs with partially 
complementary sites in the 3′-untranslated regions 
(3′-UTR) [24]. In cell patho-biology, microRNAs 
orchestrate various cellular functions and have 
been shown to play critical roles in many processes, 
including cell differentiation, apoptosis, proliferation 
and cancer development by acting either as tumour 
suppressors or oncogenes [25].
The deregulated expression of certain microRNAs 
has been primarily associated with specific genetic 
lesions implicated in CLL pathogenesis [26]. However, 
subsequent evidences collectively suggested that the 
variability in microRNA expression in CLL can also 
be due to external stimuli, including those delivered by 
genotoxic drugs or through the triggering of Toll-like 
receptor 9 or specific BCRs [27–29]. In particular, the 
up-regulation of microRNAs from the miR-132~212 
family has been recently associated with BCR triggering, 
although the functional meaning of this phenomenon has 
not been yet established [30, 31].
Here, we demonstrated that the engagement of BCR 
in CLL cells triggers, through the up-regulation of miR-
132, an inter-chained cascade of events characterized 
by: i) down-regulation of the deacetylase SIRT1 [32]; 
ii) increased acetylation of TP53; and iii) up-regulation 
of TP53 target genes. Consistently, higher miR-132 
constitutive levels were associated with a relative more 
benign clinical course of patients with M CLL.
RESULTS
anti-IgM stimulation up-regulates microRNAs 
from the miR-132~212 family
Purified CLL cells from 9 UM CLL and 7 M 
CLL were either left unstimulated or were stimulated 
with immobilized or soluble anti-IgM for 20 hours and 
separately analyzed for changes in their miRome. By 
applying an identical algorithm and P value for supervised 
analyses, miR-132 and miR-212, belonging to the same 
microRNA family [33], resulted the sole up-regulated 
microRNAs both in UM and in M CLL cells upon 
stimulation with immobilized anti-IgM (Figure 1A–1B). 
miR-132 and miR-212 turned out to be up-regulated 
upon BCR triggering by immobilized anti-IgM also 
by analyzing UM and M CLL together (Figure S1), as 
previously reported [30, 31]. Conversely, no microRNA 
modulation was observed upon stimulation with soluble 
anti-IgM (data not shown) in keeping with previous 
observations comparing the effects of BCR stimulation in 
CLL by soluble versus immobilized anti-IgM [16, 34, 35].
In order to verify the kinetic of miR-132 induction 
after anti-IgM stimulation, we performed a time course 
experiment at various time points in an independent 
CLL series (13 UM CLL and 17 M CLL). As reported 
in Figure S2A, miR-132 expression was transiently 
induced with a peak at 20 (mean fold change over control 
21.7±2.8) hours after stimulation with immobilized 
anti-IgM. On the contrary, expression of miR-132 after 
soluble anti-IgM stimulation showed only a slight up-
regulation peaking at 6 hours (mean fold change over 
control 2.76±1.03; Figure S2A).
Parallel experiments carried out by stimulating 
purified peripheral blood (PB) normal B cells (n = 4) 
with soluble and immobilized anti-IgM indicated that 
miR-132 was up-regulated after 20 hours of BCR 
stimulation, although with a smaller magnitude compared 
to immobilized anti-IgM stimulated CLL cells (Figure 
S2B) [30, 31].
microRNA profile results were validated in CLL 
cells from a wider series of 28 cases (12 UM and 16 M 
CLL), in which stimulation with immobilized anti-IgM 
(hereafter simply indicated as anti-IgM) resulted in a 
significant induction of miR-132 expression both in UM 
(mean fold change over control 21.6±4.9; P = 0.0015) and 
M CLL cells (mean fold change over control 18.2±3.1; 
P = 0.0001), with a comparable magnitude comparing UM 
and M CLL (P = 0.54; Figure 1C).
When CLL cells (4 UM and 4 M CLL) were 
concomitantly exposed in vitro to anti-IgM and the 
SYK inhibitor R406 [36], the up-regulation of miR-
132 upon anti-IgM stimulation (mean fold change over 
control 16.3±5.3; P = 0.023; Figure 1D) was completely 
abrogated (mean fold change over control 0.7±0.1; 
P = 0.127; Figure 1D), demonstrating the dependency of 
miR-132 up-regulation to BCR triggering.
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anti-IgM stimulation induces changes in mRNA 
levels of miR-132 target genes
A parallel GEP, comparing anti-IgM stimulated 
versus unstimulated CLL cells was performed utilizing 
the same RNA samples used for miRome [14, 28]. In 
UM CLL, 3,648 differentially expressed genes (1,888 
up-regulated and 1,760 down-regulated upon anti-IgM 
stimulation) were identified (Figure S3A and Table 
S1), while in M CLL a smaller set of differentially 
expressed genes (537 genes, 418 up-regulated and 119 
down-regulated; Figure S3B and Table S2) was found. 
Notably, about 75% (387/537 genes) of the latter set of 
genes was part of the signature connoting the UM CLL 
category (Figure S3C and Table S1 and Table S2), in 
keeping with the notion of a more complete response to 
BCR engagement in UM than in M CLL cells [8, 16, 37]. 
Again in agreement with these previous studies [8, 37], 
among the most significant pathways and gene ontology 
(GO) categories containing differentially expressed genes 
upon anti-IgM stimulation, both in the UM and M CLL 
groups, were those related to “Immune Response”, “B-cell 
receptor signaling pathway” and “Antigen processing and 
presentation” (Table S3 and Table S4).
Figure 1: miR-132 induction upon anti-IgM stimulation of CLL cells. A. miRome of UM CLL cells upon immobilized anti-
IgM stimulation. Hierarchical clustering of immobilized anti-IgM stimulated (red bar under the horizontal dendrogram) and unstimulated 
(blue bar under the horizontal dendrogram) UM CLL cell samples (9 cases) is shown. Color codes for microRNA expression values refer to 
mean centered log-ratio values. B. miRome of M CLL cells upon immobilized anti-IgM stimulation. Hierarchical clustering of immobilized 
anti-IgM stimulated (red bar under the horizontal dendrogram) and unstimulated (blue bar under the horizontal dendrogram) M CLL cell 
samples (7 cases) is shown. Color codes for microRNA expression values refer to mean centered log-ratio values. C. qRT-PCR analysis of 
miR-132 expression in immobilized anti-IgM stimulated and unstimulated CLL cell samples (12 UM and 16 M). D. qRT-PCR analysis of 
miR-132 expression in unstimulated CLL cells, or immobilized anti-IgM stimulated, or immobilized anti-IgM plus R406 (4 UM and 4 M). 
In all graphs data represent mean ± SEM; P values refers to Student’s t-test.
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With the aim to identify whether microRNAs 
from miR-132~212 family were able to affect the gene 
expression signature of anti-IgM stimulated CLL cells, 
we retrieved the putative miR-132 target genes from five 
different databases (i.e. miRDB, TargetScan, microRNA, 
GSEA and DIANA-Lab; Table S5) and prior published 
studied [30]. Given the heterogeneity of the different 
databases, a merged dataset was identified containing 
the putative miR-132 target genes that were present in 
at least 3 out of 5 databases (167 genes, Table S5). The 
modulation of these 167 putative miR-132 target genes in 
CLL cells upon anti-IgM stimulation was investigated by 
using a GSEA approach [38].
As shown in Figure 2A–2B, anti-IgM stimulation 
significantly down-regulated 35 and 34 of the 167 putative 
miR-132 targets in UM and M CLL cells, respectively, 
with 28 of the down-regulated miR-132 target genes being 
in common to UM and M CLL (identified by asterisks 
in Figure 2AB, right panels). Since in this context, 
genes are ranked from top to bottom according to a 
GSEA correlation score [38], we selected SIRT1 which 
resulted the top ranked gene among the 28 commonly 
down-regulated genes in UM CLL. SIRT1 encodes for a 
deacetalyse, which is a well-known regulator of the p53 
pathway in several cell systems [32, 39, 40].
SIRT1 is a direct target of miR-132
In-silico analysis identified potential miR-132 
responsive elements in the 3′-UTR of the SIRT1 gene 
(Figure S4). When a luciferase reporter construct containing 
the SIRT1 3′-UTR was co-transfected with the pre-miR-132 
in cells from the CLL-like cell line MEC1, a significant 
decrease in luciferase activity (mean fold change over 
control 0.17±0.03, P = 0.0213) was observed with respect 
to MEC1 cells co-transfected with the SIRT1 3′-UTR and 
the corresponding scrambled control (Figure 3A).
In keeping with these data, an inverse correlation 
between the constitutive expression levels of miR-132 
and SIRT1 protein levels (rho = –0.78; P = 0.0017) was 
found in primary CLL cells from 7 UM CLL and 6 M CLL 
patients (Figure 3B).
Collectively, the data obtained from the GEP 
analysis, in vitro transfection assay and ex-vivo correlative 
studies demonstrate a direct link between miR-132 and 
SIRT1 expression in CLL.
anti-IgM stimulation associates with down-
regulation of SIRT1 protein, increase of TP53 
acetylation, and activation of the TP53 pathway
As shown in Figure 4A–4B, SIRT1 protein levels 
were significantly reduced (mean fold change 0.87±0.06; 
P = 0.001) upon anti-IgM stimulation of CLL cells 
(5 UM CLL and 4 M CLL), with similar decrements 
when comparing UM and M CLL samples (P = 0.41). 
Given the activity of SIRT1, a TP53 deacetylase [32, 39, 
40], we evaluated the levels of acetylated TP53 upon 
anti-IgM stimulation in the same CLL samples. In this 
context, a significant increase in TP53 acetylation was 
observed (mean fold change 1.21±0.19; P = 0.0072; 
Figure 4A–4B) upon anti-IgM stimulation, again with similar 
trends between UM and M CLL cell samples (P = 0.61).
TP53 acetylation is known to be necessary for 
activation of the TP53 pathway and up-regulation of TP53 
target genes [39, 40]. In keeping with this notion, GEP 
analysis identified the TP53 target gene CDKN1A among 
the top-ranked genes up-regulated in anti-IgM stimulated 
CLL cells both in UM and M CLL (Table S1 and Table S2). 
Moreover, the “TP53 signaling” and “apoptosis” pathway 
were identified by both the “Pathway-Express” and GO 
analyses as gene categories that are differentially expressed 
between unstimulated and anti-IgM stimulated UM and M 
CLL cells (Table S3 and Table S4).
miR-132 enhances apoptosis in EHEB cell line
The CLL-like EHEB cell line was transfected either 
with pri-miR-132 or scrambled control and evaluated 
for apoptosis and viability after 3-5-7 days of culture. 
qRT-PCR analysis of miR-132 levels showed that transfection 
was successful, with an increase in miR-132 expression levels 
ranging from 50- to 186-fold compared to cells transfected 
with scrambled control (Figure 5A). Compared to cells 
transfected with scrambled control miR-132-transfected 
EHEB cells always showed a greater apoptotic rate which 
started at day 3 and reached the statistical significance at day 
5 (P = 0.048) and day 7 (P = 0.007) of culture (Figure 5B). 
Apoptosis was TP53 dependent as witnessed by an early 
down-regulation of SIRT1 (20 hours) and increased of 
CDKN1A in RNA occurring upon miR-132 transfection 
(Figure 5C and data not shown).
High constitutive expression of miR-132 
identifies an M CLL subset with good prognosis
Expression level of miR-132 was analyzed by 
qRT-PCR in an independent series of 134 cases (51 UM 
CLL and 83 M CLL), all with information available 
regarding TTT and the main clinical and biological 
prognostic parameters (Rai stage, IGHV mutations, 
karyotype abnormalities as detected by FISH, CD38, 
CD49d and ZAP-70 expression; Table S6).
Results of qRT-PCR evaluations showed that 
constitutive miR-132 expression levels were variable, 
ranging from negligible values to values comparable to 
those found in CLL cells stimulated for 20 hours with 
anti-IgM (mean = 1.66, range 0.08-11.00 arbitrary unit, 
a.u.; Figure S5A). Of note, the constitutive levels of 
miR-132 in normal PB B cells from 14 healthy donors 
had similar mean values (1.26 a.u.) but with a narrower 
variability (range 0.10-2.66 a.u.; Figure S5A) in keeping 
with results of in vitro stimulation experiments (Figure 
S2B). The variability in constitutive miR-132 expression 
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values, as detected in CLL cells, was not associated with 
any of the main biological prognostic markers, including 
IGHV mutation status, high-risk cytogenetic abnormalities 
or ZAP-70, CD38 and CD49d expression (Figure S5B). 
On the other hand, all these variables were proven to be 
significant predictors for TTT in this series (Table S7 and 
Figure S6), in keeping with previous studies [2, 41].
By setting a cut-off to the median expression value 
(1.27 a.u.), the median TTT of the 67 CLL patients with 
miR-132 expression levels above the cut-off was significantly 
longer than the median TTT of the 67 cases with miR-132 
expression levels below the cut-off (68 versus 39 months, 
respectively, P = 0.0216; Figure 6A and Table S7). However, 
when the prognostic impact of miR-132 expression was 
Figure 2: Gene set enrichment analysis (GSEA) of anti-IgM stimulated CLL cells. A. GEP data of UM CLL cells stimulated 
with immobilized anti-IgM were tested for an enrichment of the gene set of miR-132 gene targets, as retrieved from different database for 
microRNAs targets (see Supplementary Information). GSEA resulted significantly enriched in down-regulated genes in the immobilized 
anti-IgM stimulated sample group. B. GEP data of M CLL cells stimulated with immobilized anti-IgM were tested for an enrichment of 
the gene set of miR-132 gene targets, as retrieved from different database for microRNAs targets (see Supplementary Information). GSEA 
resulted significantly enriched in down-regulated genes in the immobilized anti-IgM stimulated sample group. For each panel, a plot of 
the Enrichment Score (ES) versus the gene list index is shown on the left; the corresponding heat-map highlighting the relative expression 
of the gene members belonging to the miR-132 gene set in immobilized anti-IgM stimulated (red bar) and unstimulated (blue bar) CLL is 
reported on the right. Asterisks indicate genes in common between UM and M CLL; arrows indicate SIRT1 gene.
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Figure 3: miR-132 mediates SIRT1 down-regulation. A. miR-132 mediates translational repression of SIRT1 through a binding 
site in SIRT1 3′-UTR. MEC1 cells were cotransfected with pMIRTarget vector containing the 3′-UTR of SIRT1 (Luc-SIRT1 3′-UTR) and 
pre-miR-132 (closed histogram) or scrambled control (shaded histogram). Luciferase assay were performed using dual-luciferase assay 
system after 20-22 hours after transfection. Data represent mean ± SEM of three biological replicates; P values refers to Student’s t-test. 
B. Correlation between miR-132 and SIRT1 expression in 13 primary CLL samples. Constitutive miR-132 levels were measured by qRT-
PCR. Constitutive SIRT1 protein levels were determined by western blotting. The relative expression of miR-132 was plotted against that 
of SIRT1. rho indicates the Spearman’s coefficient and P value indicates the significance level of correlation.
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separately tested in the UM and M CLL subgroups, miR-132 
expression retained its favourable clinical significance only 
in the context of M CLL. As shown in Figure 6, the median 
TTT of the 43 M CLL patients with high miR-132 levels was 
significantly longer than the median TTT of the 40 M CLL 
patients with low miR-132 levels (102 versus 60 months, 
respectively, P = 0.0050; Figure 6B), while in the context 
of UM CLL the median TTT was comparable irrespective 
of the level of miR-132 (P = 0.97; Figure 6B). Consistently, 
multivariate Cox proportional hazard analysis showed that 
miR-132 behaved as a favorable marker for TTT prediction 
both in the whole CLL series (HR = 0.57; P = 0.0286) and 
in the context of M CLL (HR = 0.41; P = 0.0246; Table S8 
and Table S9), but not in UM CLL (not shown).
Figure 4: Effects of anti-IgM stimulation of CLL cells on SIRT1 protein levels and TP53 acetylation levels. A. Dot and 
line diagrams indicating the changes in SIRT1 protein expression levels or TP53 acetylation levels upon immobilized anti-IgM stimulation 
are reported as left or right panel, respectively. Unbroken line refers to UM CLL cases and dotted line refers to M CLL cases; P values refer 
to paired t-test. B. Comparative evaluation of SIRT1 protein levels and TP53 acetylation levels in 4 (2 UM and 2 M) representative CLL 
cases, as assessed by western blotting. β-Actin levels were used as loading control in all cases.
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DISCUSSION
In this study, we have examined in detail the 
miRome changes following the activation of the BCR 
signaling pathway using anti-IgM as a surrogate for 
antigen engagement [34]. In particular, confirming 
previous results [30, 31], we demonstrated that CLL cells, 
irrespective of their IGHV mutational status, respond 
to BCR stimulation with a clear-cut miRome signature 
basically characterized by the up regulation of miR132 
and miR212, two microRNA belonging to the same cluster 
[33]. The capacity of the BCR pathway to regulate miR-
132 expression was further validated by demonstrating 
that up-regulation of miR-132: i) requires sustained BCR 
signaling, as it is significantly higher upon exposure of 
CLL cells to immobilized compared to soluble anti-IgM, 
in keeping with literature data on BCR functionality 
in CLL [16, 34, 35]; ii) is specifically induced by 
BCR engagement since it is completely abrogated by 
co-exposing CLL cells to the SYK inhibitor R406 [36]; 
iii) occurs also in normal B cells either stimulated with 
soluble or immobilized anti-IgM, although the magnitude 
of the phenomenon is much lower. The higher variability 
in the constitutive levels of miR-132 in circulating CLL 
cells compared to normal B cell is also consistent with the 
modulation of miR-132 expression in vivo allegedly due 
to the continuing antigenic stimulation occurring in CLL 
tissue sites [6–8].
Several target genes have been described for 
miR-132, including mediators of neurological development, 
heart pathology, synaptic transmission, inflammation 
and angiogenesis [42–44]. As shown here in the setting 
of CLL, and in keeping with other reports [30, 31] 
miR-132 turned out to be an important regulator of the 
gene expression profile induced by anti-IgM stimulation. 
Of note, among the top-ranked miR-132 target genes 
identified in our analysis as down-regulated by anti-IgM 
stimulation both in UM and M CLL cells, was SIRT1, a 
gene encoding for a class III nuclear deacetylase targeting 
several histonic and non-histonic proteins including 
Figure 5: miR-132 enhances apoptosis and survival in CLL-like EHEB cell line. A. Effective transfection of miR-132. Over-
expression of miR-132 in EHEB cell line transfected with pri-miR-132 compared to the same cell line transfected with scrambled control. 
B. Apoptosis of EHEB cells transfected with miR-132 or scrambled control. The percentage of apoptotic EHEB cells transfected wit miR-
132 was measured with AnnexinV/7-AAD staining in flow cytometry and normalized to the percentage of EHEB cells transfected with 
scrambled control. Dotted line indicates scrambled control transfected cells and solid line indicates miR-132 transfected cells. P value 
(Student’s t-test) for each time-point are shown. Data represent mean ± SEM of four biological replicates. C. miR-132 over-expression and 
SIRT1 protein levels. Effects of miR-132 over-expression on SIRT1 protein levels in EHEB cells. Comparative evaluation of SIRT1 protein 
levels in EHEB cells, as assessed by western blotting. β-Actin levels were used as loading control in all cases.
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TP53, Ku70, and FOXO [45–48]. A direct functional link 
between miR-132 and SIRT1 in CLL was demonstrated 
by taking advantage of the CLL-like models MEC1 
and EHEB, in which an ad-hoc luciferase assay and the 
transfection of microRNA precursor of miR-132 clearly 
showed the capability of miR-132 to directly down-
regulate SIRT1 expression, as also found in other cell 
systems [45]. The inverse correlation between miR-132 
expression and SIRT1 protein levels that we observed 
in primary CLL samples, again underlines the close 
relationship between SIRT1 and miR-132 in CLL.
In keeping with the evidence that SIRT1 inactivates 
TP53 by deacetylating a critical lysine residue at position 
382 [39], we demonstrated a significant increase of TP53 
Figure 6: miR-132 expression levels are associated with a better clinical outcome. A. Kaplan-Meier curves obtained by 
comparing TTT intervals of 67 CLL cases with miR-132 levels above the median value (median TTT 68 months), and with miR-132 levels 
below the median value (median TTT 39 months). B. Kaplan-Meier curves obtained by comparing TTT intervals of M CLL with miR-132 
levels above the median value (median TTT 100 months), M CLL with miR-132 levels below the median value (median TTT 60 months), 
UM CLL with miR-132 levels above the median value (median TTT 28 months) and UM CLL with miR-132 levels below the median value 
(median TTT 28 months). The median relative expression level of the series of 134 CLL cases was 1.27 a.u.. The number of patients (pts) 
included in each group is reported in parenthesis; the reported p value refers to log-rank test.
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acetylation at lys382 upon anti-IgM stimulation of CLL 
cells. This increase, being instrumental in preventing 
the ubiquitination of lysine residues and the subsequent 
proteasomal degradation of TP53 [39], represents a pre-
requisite for TP53 pathway activation [40]. In agreement 
with these observations, the TP53 target gene CDKN1A 
resulted significantly up-regulated both in UM and M 
CLL cells upon anti-IgM stimulation, along with other 
key genes belonging to the gene ontology categories 
“apoptosis” and/or “p53 signaling pathway”. Of note, 
the up-regulation of genes from the TP53 pathway was 
recently found by Herishanu et al [8] to be associated with 
the gene expression signature related to BCR pathway 
activation characteristic of CLL cells from CLL-involved 
lymph nodes. Moreover, activation of the TP53 pathway 
upon BCR triggering was also revealed by re-analyzing the 
GEP data associated with miR-132 up-regulation reported 
by Pede et al. [30] (RB, personal communication), and 
overtly reported by Tavolaro et al. [31], although not 
associated with the down-regulation of the miR-132 target 
SIRT1. Finally, using a similar GEP approach, Vallat et 
al [19] provided evidence for activation of a proapoptotic 
transcriptional program in CLL cells at later time points 
after BCR stimulation. In keeping with these data, the 
ectopic expression of miR-132 in EHEB cells triggered 
a TP53-dependent apoptotic pathway, as documented by 
the early down-regulation of SIRT1 and the up-regulation 
of CDKN1A mRNA. Altogether, these data suggest that 
activation of apoptotic pathway(s), such as the miR-132/
SIRT1/TP53 axis, is a common feature of the response of 
CLL cells to BCR triggering.
Although the role of the activation of the miR-132/
SIRT1/TP53 pathway in CLL remains obscure, it may 
represent part of a normal negative feedback mechanism 
to limit B cell expansion or eliminate autoreactive B 
cells. In support of this hypothesis are the observations 
that SIRT1 levels in normal B cells are generally lower 
than in CLL cells [49], and that BCR stimulation in 
normal B cells also results in a substantial induction of 
miR-132, as shown here and previously [30, 31]. 
Moreover, experiments performed with different Eu-TCL1 
mouse models resembling progressive/non-anergic and 
indolent/anergic diseases, as recently published by some 
of us [50], showed that miR-132 and miR-212 expression 
levels were significantly higher in the neoplastic B 
cell component of mice with indolent/anergic disease, 
further supporting the hypothesis of a negative feedback 
mechanism regulated by miR-132 operating also in this 
CLL model (S.G. and D.G.E., personal observation).
A number of studies have indicated that signaling 
through the BCR may be largely responsible for the different 
clinical course and outcome in patients with CLL expressing 
either UM or M IGHV genes [12, 18, 34, 51]. In vitro 
experiments have reported heterogeneous and somewhat 
conflicting results regarding the response of CLL cells to 
anti-IgM stimulation, ranging from increased cell death to 
suppression of apoptosis and cell proliferation, although the 
latter response is usually very modest [16, 19, 23, 37, 52–54]. 
Moreover, besides BCR stimulation, other co-stimulatory 
signals, allegedly present in a suitable micro-environment in 
vivo, could contribute to induce proliferation and/or provide 
pro-survival signals to CLL cells [28, 55–62].
In the present study, we describe for the first time a 
complete and inter-chained cascade of events, occurring in 
both M and UM CLL cells, triggered by BCR engagement 
via miR-132 up-regulation and sequentially characterized 
by SIRT1 down-regulation, TP53 acetylation and 
TP53 pathway activation. It can be speculated that this 
miR-132/SIRT1/TP53 axis represents the prevalent 
pathway activated in M CLL cells upon BCR triggering in 
vivo, while in UM CLL cells the activity of this pathway is 
overcome by additional pathways triggered by other types 
of antigens or other exogenous stimuli that may transmit 
more efficient pro-survival and/or proliferative signals to 
these cells (Figure 7) [28, 55–62]. The availability of such 
signals, or the capacity of the CLL cells, expressing either 
a UM or M IGHV gene, to differently respond to these 
external stimuli could provide a putative explanation for 
the different biological and clinical behavior of the UM 
and M CLL subsets (Figure 7). The finding that high levels 
of miR-132 are associated with a less aggressive clinical 
behaviour in the context of M CLL but not in UM CLL is 
in keeping with this reasoning.
Currently, several inhibitors of kinases downstream 
the BCR have been developed in clinical trials, and have 
emerged as promising novel therapies for CLL patients. 
These agents include inhibitors of SYK, BTK and PI3Kδ 
[11, 63–65]. Typically, these agents operate by thwarting 
the BCR signal as well as signals activated in response 
to other ligands that mediate the cross-talk between CLL 
cells and the tumour microenvironment [63, 65]. Recently, 
differences emerged regarding the capability of CLL to 
respond to BTK inhibitors [66], and, in particular, M CLL 
patients may have an inferior response when compared 
to patients with UM CLL [64]. In this context, the up-
regulation of miR-132 upon BCR triggering and its specific 
abrogation upon exposure to the SYK inhibitor R406, as 
reported here, opens the possibility that in some instances, 
e.g. in M CLL, the down-regulation of the miR-132/
SIRT1/TP53 axis by BCR inhibitors may paradoxically 
attenuate the clinical effects of BCR inhibitors in CLL.
METHODS
Primary cells from CLL patients and healthy 
donors
The study included PB samples from 178 CLL 
patients, divided as follows: i) a discovery panel of 16 
CLL cases utilized for global microRNA expression 
profile (miRome) and gene expression profiling (GEP) 
analyses; ii) a validation panel of additional 28 CLL cases 
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utilized for functional assays; iii) a third panel of 134 
CLL cases, with Time-To-first-Treatment (TTT) intervals 
available [67], utilized for clinical correlation studies. 
All patients provided informed consent in accordance 
with local Institutional Review Board requirements 
(IRB-04-2010, Centro di Riferimento Oncologico, Aviano, 
Italy) and declaration of Helsinki. PB mononuclear 
cells were separated by Ficoll gradient centrifugation 
(Amersham Biosciences, Uppsala, Sweden). Detection 
of IGHV mutational status was performed as previously 
reported [29]. The 2% cutoff was chosen to discriminate 
UM versus M CLL cases. IGHV mutational status and 
additional biological features of CLL cases entering this 
study, including expression of CD38, CD49d, ZAP-70, 
interphase fluorescence in-situ hybridization (FISH) for 
the main chromosomal abnormalities, Rai stage, and the 
experiments for which each sample has been used are 
listed in Table S6 [1, 29, 41].
The purity of the CLL cells, as monitored by flow-
cytometry, always exceeded 95% of clonal CD5+/CD19+ 
cells. Whenever necessary, CLL cells were purified by 
negative selection using anti-CD3, anti-CD14 and anti-
CD16 mouse monoclonal antibodies and Dynabeads 
coated with a pan anti-mouse IgG antibody (Dynal 
Biotech, Oslo, Norway) [56].
Normal B cells from healthy donors (n = 18) 
were obtained from peripheral blood samples by Ficoll- 
gradient centrifugation and used either directly or 
cryopreserved until use. All studies were performed on 
highly purified cells (>95% pure), as results of negative 
selection by immunomagnetic beads when required [68].
Cell culture conditions
Highly purified CLL cells and normal B cells were 
cultured (1 × 107 cells/ml) in RPMI-1640 supplemented with 
10% heat-inactivated fetal bovine serum, 100 U/ml penicillin, 
0.1 mg/ml streptomycin, 2 mM L-glutamine and 1 mM 
sodium pyruvate (Life Technologies, Carlsbad, CA, USA). 
CLL cells were stimulated, according to previous studies 
[16, 36], at various time points with 10 μg/ml goat F(ab’)2 
anti-human IgM (soluble anti-IgM) (SouthernBiotech, 
Birmingham, AL) or with 1 × 107/mL Dynabeads M-450 
Epoxy (Life Technologies) coated with 10 μg goat anti-human 
IgM (immobilized anti-IgM) (SouthernBiotech, Birmingham, 
AL) [56]. The coating procedure was done according to the 
manufacturer’s instructions (Life Technologies). In selected 
experiments, CLL cells were co-stimulated with immobilized 
anti-IgM and cultured in the presence of R406 4 μM (Axon 
Medchem, The Netherlands) as previously described [36].
miRome, GEP and data mining tools
Total RNA was extracted from purified CLL cells 
using the TRIZOL Reagent (Life Technologies) and 
validated for integrity and purity using the Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA).
Single-color hybridization microarray experiments 
for miRome were performed with 100 ng total RNA/
sample labeled with Cyanine(Cy)-3 dye using the 
microRNA Complete Labeling System & Hyb Kit (Agilent 
Technologies). Cy3-labeled RNA was hybridized to the 
Human microRNA microarray Version 3 from the Sanger 
database v12.0 (Agilent Technologies).
Figure 7: The miR-132/SIRT1/TP53 axis and other BCR-related pathways operating in M and UM CLL. See text for 
details. Up-regulations and down-regulations are indicated by a red arrow or a green arrow, respectively.
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GEP was performed using the Whole Human 
Genome (4x44K) oligo microarray platform (Agilent 
Technologies) as previously described [28, 29]. Microarray 
slides were analyzed with an Agilent Microarray Scanner 
(Agilent Technologies).
The hybridization signal values for the multiple 
probes were obtained with the use of Agilent Feature 
Extraction Software 10.7.3 (Agilent Technologies). 
Microarray data are available in Gene Expression 
Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) under 
accession number GSE52776.
Bioinformatics analyses were performed using 
GeneSpringGX 11.5 (Agilent Technologies). Results 
were visualized by hierarchical clustering applying Ward’s 
method with Euclidean distance.
The specific targets for miR-132 targets were 
identified by taking advantage of the following five 
datasets for putative microRNA targets: i) GSEA 
(http://www.broadinstitute.org/gsea/msigdb/cards/
GACTGTT,MIR-212,MIR-132.html); ii) microRNA 
(http://www.microrna.org/microrna/home.do); iii) miRDB 
(http://mirdb.org/miRDB/index.html); iv) Targetscan 
(http://www.targetscan.org/vert_50/); v) DIANA (http://
diana.cslab.ece.ntua.gr/microT/). In particular, among 959 
putative miR-132 target genes overall comprised in the 
above quoted five datasets (Table S5), we selected those 
shared by at least three out of five datasets; this resulted 
in the identification of 167 putative miR-132 target genes 
that were up-loaded to the Gene Set Enrichment Analysis 
(GSEA) software [38], for subsequent analyses (Table S5). 
Further details are provided in Supplementary Information.
Quantitative-real-time polymerase chain 
reactions (qRT-PCR)
Expression of selected microRNAs and of the 
control RNU6B was assessed using a standard TaqMan 
MicroRNA assay kit (Life Technologies) according to the 
manufacturer’s instructions and as previously described 
[28, 29]. Briefly, microRNA was reverse transcribed to 
cDNA using gene-specific primers and the relative amount 
of each microRNA was computed using the equation 2-ΔCt, 
where ΔCt = (Ct microRNA – Ct RNUB6).
Luciferase assay
Cells from the CLL-like cell line MEC1 (0.5-1 × 105 
cells per well) were seeded in 96-well plates. After 24 hours, 
100 ng pMIRTarget vector containing the 3′-UTR of SIRT1 
(OriGene Technologies, Rockville, MD), 10 ng Renilla 
vector (Promega Corporation, Madison, WI), and 100 ng 
pre-miR-132 or 100 ng scrambled control oligonucleotides 
(Life Technologies) were transfected using Fugene HD 
transfection reagent (Promega Corporation) according to 
the manufacturer’s instructions. Luciferase assays were 
performed using the dual-luciferase assay system (Promega 
Corporation) 20-22 hours after transfection.
Transfection
Three micrograms of microRNA precursor for 
miR-132 (Ambion, TX) were transfected into 5 × 106 CLL-
like cell line EHEB cells with the Amaxa Nucleofector 
system (Lonza Cologne GmbH, Germany) according 
to manufacturer’s guidelines. As negative control, cells 
were transfected with equal amounts of pre-miR-negative 
control#1 (Ambion).
Western blot
Total proteins were extracted from EHEB or CLL 
cells collected 20 hours after transfection or co-stimulation 
with immobilized anti-IgM, loaded and run in NuPAGE 
Novex 4-12% Bis-Tris gels (Life Technologies) prior 
to transfer to nitrocellulose membranes (GE Healtcare, 
UK) for Western Blot analysis and detection by ECL 
(GE Healtcare) or Immobilon (Millipore Corporation, 
MA). Rabbit-anti-SIRT1 (C14H4) (Cell Signaling 
Technology, Danvers, MA), Rabbit-anti-acetyl-p53 
(Lys382) (Cell Signaling Technology) antibodies (final 
dilution 1:1000) were used for protein detection. Anti-beta 
Actin antibody (AC-15) (HRP) (Abcam, UK) was used for 
loading control (final dilution 1:100.000). Densitometric 
quantitation of western blots was determined with the 
Quantity One 4.1.0 software (Bio-Rad).
Functional studies
MicroRNA-transfected EHEB cells were cultured in 
RPMI-1640 for 7 days. The percentage of apoptotic cells 
was determined by AnnexinV and 7-amino-actinomycin-D 
(7-AAD) (Becton-Dickinson, San Jose, CA) staining. 
Data were acquired on a FACS Canto flow cytometer and 
analysed by the FACS Diva software (Becton-Dickinson).
Statistical analysis
Clinical correlations, performed with the MedCalc 
v9.5 software, were made using Kaplan-Meier plots and 
log-rank test; TTT was chosen as clinical endpoint. The 
Cox proportional hazard regression model was used 
to assess the independent effect of co-variables, treated 
as dichotomous on TTT, with a stepwise procedure for 
selecting significant variables.
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